Role of Pten in Leukemia Stem Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2011 Feb 8

PMID 21297225

Citations 22

Authors

Cong Peng

Yaoyu Chen

Dongguang Li

Shaoguang Li

Affiliations

Soon will be listed here.

Abstract

Chronic myeloid leukemia (CML) is initiated from the BCR-ABL-expressing leukemia stem cells (LSCs). These LSCs are highly resistant to BCR-ABL kinase inhibitors, imatinib, dasantinib and nilotinib, and methods for eradication of LSCs are still not available. It is critical to identify genes that play roles in survival and proliferation of LSCs. We recently discovered that the tumor suppressor gene Pten is downregulated in LSCs of CML mice. By genetic deletion or overexpression of Pten, we confirmed that Pten functions as a tumor suppressor in LSCs of CML, consistent with the role of Pten in LSCs of acute myeloid leukemia (AML) and progenitor cells of T-ALL progenitors. Functional enhancement of the Pten pathway provides a therapeutic strategy for targeting LSCs.

Citing Articles

The Role of PTEN in Chemoresistance Mediated by the HIF-1α/YY1 Axis in Pediatric Acute Lymphoblastic Leukemia.

Antonio-Andres G, Morales-Martinez M, Jimenez-Hernandez E, Huerta-Yepez S Int J Mol Sci. 2024; 25(14).

PMID: 39063014 PMC: 11276810. DOI: 10.3390/ijms25147767.

Downregulation of Stearoyl-CoA Desaturase 1 (SCD-1) Promotes Resistance to Imatinib in Chronic Myeloid Leukemia.

Altinok Gunes B, Hekmatshoar Y, Ozkan T, Bozkurt S, Erdogan Aydos O, Buyukasik Y Mediterr J Hematol Infect Dis. 2023; 15(1):e2023008.

PMID: 36660357 PMC: 9833301. DOI: 10.4084/MJHID.2023.008.

PTEN Tumor-Suppressor: The Dam of Stemness in Cancer.

Luongo F, Colonna F, Calapa F, Vitale S, Fiori M, De Maria R Cancers (Basel). 2019; 11(8).

PMID: 31366089 PMC: 6721423. DOI: 10.3390/cancers11081076.

Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.

Podshivalova K, Wang E, Hart T, Salomon D Leuk Res. 2018; 74:1-9.

PMID: 30269036 PMC: 6290994. DOI: 10.1016/j.leukres.2018.09.009.

Virosecurinine induces apoptosis in human leukemia THP-1 cells and other underlying molecular mechanisms.

Zhang G, Gao X, Zeng H, Li Y, Guo X Oncol Lett. 2018; 15(1):849-854.

PMID: 29399150 PMC: 5772865. DOI: 10.3892/ol.2017.7437.

References

Covey T, Edes K, Fitzpatrick F . Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene. 2007; 26(39):5784-92. DOI: 10.1038/sj.onc.1210391. View

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J . Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-8. View

Stiles B, Groszer M, Wang S, Jiao J, Wu H . PTENless means more. Dev Biol. 2004; 273(2):175-84. DOI: 10.1016/j.ydbio.2004.06.008. View

Chen Y, Li D, Li S . The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell Cycle. 2009; 8(21):3488-92. DOI: 10.4161/cc.8.21.9852. View

Yilmaz O, Valdez R, Theisen B, Guo W, Ferguson D, Wu H . Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006; 441(7092):475-82. DOI: 10.1038/nature04703. View

Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-7. DOI: 10.1056/NEJM200104053441401. View

Wong S, Witte O . The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004; 22:247-306. DOI: 10.1146/annurev.immunol.22.012703.104753. View

Cortes J, OBrien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 104(7):2204-5. DOI: 10.1182/blood-2004-04-1335. View

10.

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

11.

Bhatia R, Holtz M, Niu N, Gray R, Snyder D, Sawyers C . Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101(12):4701-7. DOI: 10.1182/blood-2002-09-2780. View

12.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

13.

Copland M, Hamilton A, Elrick L, Baird J, Allan E, Jordanides N . Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-9. DOI: 10.1182/blood-2005-07-2947. View

14.

Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305(5682):399-401. DOI: 10.1126/science.1099480. View

15.

Jorgensen H, Allan E, Jordanides N, Mountford J, Holyoake T . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007; 109(9):4016-9. DOI: 10.1182/blood-2006-11-057521. View

16.

Bruns I, Czibere A, Fischer J, Roels F, Cadeddu R, Buest S . The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 2009; 23(5):892-9. DOI: 10.1038/leu.2008.392. View

17.

Rossi D, Jamieson C, Weissman I . Stems cells and the pathways to aging and cancer. Cell. 2008; 132(4):681-96. DOI: 10.1016/j.cell.2008.01.036. View

18.

Weisberg E, Griffin J . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000; 95(11):3498-505. View

19.

Westbrook C, Hooberman A, Spino C, Dodge R, Larson R, Davey F . Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood. 1992; 80(12):2983-90. View

20.

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View